JumpCan

3月23日，济川药业与全亿健康就创新药泽立美®（本维莫德乳膏）达成深度合作，泽立美®在全亿健康旗下全国连锁药店首发上市。作为中美日三国同步获批的非激素类皮肤新药，泽立美®的上市标志着我国特应性皮炎治疗领域迎来全新突破，为2岁及以上儿童和成人轻中度特应性皮炎（湿疹）患者带来了优质治疗选择。

On March 23, JumpCan Pharmaceutical and Pharmplus entered into a deep collaboration for the global Class 1 innovative drug Benvitimod Cream (Zelimei), marking its debut launch in Pharmplus's national chain pharmacies. As a non-hormonal dermatological new drug approved simultaneously in China, the United States, and Japan, the commercialization of Zelimei marks a new breakthrough in China's atopic dermatitis treatment landscape, bringing an excellent treatment option for patients aged 2 years and older with mild to moderate atopic dermatitis (eczema).

Together for Shared Success

At the signing ceremony, Wan Mingzhi, CEO of Pharmplus Industry Group, and Wang Xiaobing, Deputy General Manager of JumpCan Pharmaceutical Group, engaged in in-depth exchange and expressed shared anticipation for the upcoming collaboration. Through coordinated joint effort, both parties will promote the full-scale distribution of Zelimei across online and offline stores, ensuring this high-quality innovative drug benefits more patients.

The Treatment Dilemma of Atopic Dermatitis: Steroid Dependence and Recurrence

Atopic dermatitis (eczema) is a common chronic, recurrent, inflammatory skin disease, primarily manifesting as intense itching and dry skin, erythema, and exudate. The incidence is relatively high among Chinese children — particularly infants and toddlers — severely affecting the quality of life of patients and their families. For a long time, topical treatment of atopic dermatitis (eczema) has primarily relied on corticosteroids. For children aged 2 and above, the choice of non-hormonal topical drugs has been limited, leaving many families trapped in the dilemma of "fearing side effects when using medication, but relapsing when stopping."

Zelimei: Breaking Through the Core Pain Points of Traditional Atopic Dermatitis Treatmen

As the world's first globally approved topical aryl hydrocarbon receptor (AhR) modulator for the treatment of atopic dermatitis in children aged 2 years and older and adults, Zelimei (Benvitimod Cream) fills the gap where "efficacy and safety cannot be achieved simultaneously" in non-hormonal topical treatment for young eczema patients. Zelimei exerts its therapeutic effect by inhibiting inflammation, repairing the skin barrier, regulating the microbiome, and countering oxidative stress — achieving therapeutic breakthroughs while ensuring safety, effectively addressing the clinical pain points of traditional treatments including limited efficacy, obvious side effects, and easy relapse upon discontinuation, providing safer and more effective treatment solutions for pediatric and adult eczema patients.

In this strategic collaboration, Pharmplus, with its nationwide retail network and professional pharmaceutical service system, has become Zelimei's debut channel partner. The inclusion of Zelimei is both a precise response to patient needs and a demonstration of the brand's responsibility in professionally safeguarding family health. Going forward, JumpCan Pharmaceutical will also continue to promote the deployment of Zelimei in more chain pharmacy stores and commercial sales, and through strategic coordination with retail partners — continuously integrating the resource advantages of both parties, adopting professional training, digital marketing, and other initiatives — ensure that drugs safely and efficiently reach patients, translating more pharmaceutical innovation achievements into tangible health benefits, and injecting momentum into the construction of a new hierarchical medical care system and the implementation of the Healthy China strategy.

Looking to the future, JumpCan Pharmaceutical will also accelerate the construction of the retail terminal network, build a drug accessibility service system by optimizing supply chain management and strengthening professional service capabilities. Leveraging an intelligent warehousing system, the company will achieve efficient flow of drugs from the production line to patients' hands, substantially shorten patients' waiting time for medication, improve drug accessibility, and contribute JumpCan's strength to advancing high-quality medical resource distribution and improving the health of the entire population.